BR0103913A - Tratamento de combinação para depressão e ansiedade - Google Patents

Tratamento de combinação para depressão e ansiedade

Info

Publication number
BR0103913A
BR0103913A BR0103913-0A BR0103913A BR0103913A BR 0103913 A BR0103913 A BR 0103913A BR 0103913 A BR0103913 A BR 0103913A BR 0103913 A BR0103913 A BR 0103913A
Authority
BR
Brazil
Prior art keywords
anxiety
depression
combination treatment
antagonist
cns
Prior art date
Application number
BR0103913-0A
Other languages
English (en)
Inventor
Susan Beth Sobolov-Jaynes
Christopher Joseph Schmidt
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0103913A publication Critical patent/BR0103913A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

"TRATAMENTO DE COMBINAçãO PARA DEPRESSãO E ANSIEDADE". A invenção presente diz respeito a um método de tratar a depressão ou a ansiedade num mamífero, incluindo um humano, administrando ao mamífero um antagonista de NK-1 que penetre o SNC (por exemplo um agonista de receptor de substância P) em combinação com um antagonista de receptor 5HT~ 1D~. Ela também diz respeito a composições contendo um veículo farmaceuticamente aceitável, um antagonista de NK-1 que penetre o SNC e antagonista de receptor 5HT~ 1D~
BR0103913-0A 2000-09-06 2001-09-06 Tratamento de combinação para depressão e ansiedade BR0103913A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23025700P 2000-09-06 2000-09-06

Publications (1)

Publication Number Publication Date
BR0103913A true BR0103913A (pt) 2002-05-21

Family

ID=22864516

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0103913-0A BR0103913A (pt) 2000-09-06 2001-09-06 Tratamento de combinação para depressão e ansiedade

Country Status (6)

Country Link
US (1) US20020049211A1 (pt)
EP (1) EP1186318A3 (pt)
JP (1) JP2002121153A (pt)
BR (1) BR0103913A (pt)
CA (1) CA2356797A1 (pt)
MX (1) MXPA01008993A (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0109871D0 (en) * 2001-04-20 2001-06-13 Glaxo Group Ltd Metering method for particulate material
SK252004A3 (sk) * 2001-07-20 2005-03-04 Pfizer Products Inc. Použitie antagonistov receptora NK-1 na výrobu liečiva na liečenie abnormálneho úzkostného správania domácich zvierat a spôsob screeningu skúšanej zlúčeniny s cieľom stanoviť anxiolytickú účinnosť u psov
US7235573B2 (en) * 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
WO2004031190A1 (en) * 2002-10-04 2004-04-15 Merck Sharp & Dohme Limited Azabicyclic amine derivatives as nk-1 receptor antagonists
EP1737466A1 (en) * 2004-01-29 2007-01-03 Pfizer Products Inc. COMBINATION OF y-AMINOBUTYRIC ACID MODULATORS AND 5-HT-1b RECEPTOR ANTAGONISTS
JP4880583B2 (ja) * 2004-03-17 2012-02-22 ファイザー・プロダクツ・インク 新規なベンジル（ベンジリデン）−ラクタム誘導体
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
WO2005107808A2 (en) * 2004-05-11 2005-11-17 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
MX2007014114A (es) 2005-05-10 2008-03-14 Intermune Inc Derivados de piridona para modular el sistema de proteina cinasa activada por estres.
CA3034994A1 (en) 2008-06-03 2009-12-10 Intermune, Inc. Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders
JPWO2013161871A1 (ja) * 2012-04-25 2015-12-24 興和株式会社 Ｔｌｒ阻害作用を有するチオフェン誘導体
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
EP0532527B1 (en) * 1990-06-01 1994-11-09 Pfizer Inc. 3-amino-2-aryl quinuclidines, process for their preparation and pharmaceutical compositions containing them
PL167568B1 (pl) * 1990-07-23 1995-09-30 Pfizer Sposób wytwarzania nowych pochodnych chinuklidyny PL PL
EP0573522B1 (en) * 1991-03-01 1994-12-14 Pfizer Inc. 1-azabicyclo[3.2.2]nonan-3-amine derivatives
RU2103269C1 (ru) * 1991-05-31 1998-01-27 Пфайзер Инк. Производные хинуклидина или их фармацевтически приемлемые соли и фармацевтическая композиция
UA39168C2 (uk) * 1991-06-20 2001-06-15 Пфайзер, Інк. Фторалкоксифенільні похідні піперидину або хінуклідину, що є антагоністами речовини p і фармацевтична композиція на їх основі
TW202432B (pt) * 1991-06-21 1993-03-21 Pfizer
DK0607164T3 (da) * 1991-09-26 2002-06-17 Pfizer Kondenserede tricykliske nitrogenholdige heterocykliske forbindelser som substans P-receptorantagonister
ATE194340T1 (de) * 1992-12-10 2000-07-15 Pfizer Aminomethylen substituierte heterocyclische verbindungen und ihre verwendung alssubstanz p antagonisten
JP2832754B2 (ja) * 1993-03-04 1998-12-09 ファイザー・インク． サブスタンスｐアンタゴニストとしてのスピロアザ環式誘導体
ATE172187T1 (de) * 1994-03-26 1998-10-15 Smithkline Beecham Plc Biphenyl-derivate als 5ht1d antagonisten
GB9416972D0 (en) * 1994-08-23 1994-10-12 Smithkline Beecham Plc Carbon side chain/indole/indolene
ES2155601T3 (es) * 1995-07-07 2001-05-16 Pfizer Compuestos de benzolactama sustituidos como antagonistas de la sustancia p.
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
FR2744449B1 (fr) * 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
ATE333879T1 (de) * 1996-10-07 2006-08-15 Merck Sharp & Dohme Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
TW426667B (en) * 1997-11-19 2001-03-21 Pfizer Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists

Also Published As

Publication number Publication date
EP1186318A3 (en) 2003-03-26
EP1186318A2 (en) 2002-03-13
MXPA01008993A (es) 2004-11-10
CA2356797A1 (en) 2002-03-06
JP2002121153A (ja) 2002-04-23
US20020049211A1 (en) 2002-04-25

Similar Documents

Publication Publication Date Title
BR0103913A (pt) Tratamento de combinação para depressão e ansiedade
BR9914901A (pt) Agonistas do receptor 5ht1 e metoclopramida para o tratamento de enxaqueca
BR0200283A (pt) Composições farmacêuticas para o tratamento de distúrbios do snc e de outros distúrbios
BR0106462A (pt) Composições farmacêuticas para distúrbios do snc e outros distúrbios
HK1074573A1 (en) Tetrahydroquinoline analogues as muscarinic agonists
HUP0301920A2 (hu) P anyag receptor antagonista és magnézium vegyület kombinációját tartalmazó agy-, gerinc- és idegsérülés kezelésére szolgáló injekciós készítmény
BR9812886A (pt) Uso de um atagonista de recptor de 5-ht3 ou de um seu derivado farmaceuticamente aceitável, processo para tratamento de ibs em fêmeas não-constipadas, e, antagonista de recpetor de 5-ht3 ou seu derivado farmaceuticamente aceitável
MXPA04006280A (es) Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
MY116002A (en) Nk-1 receptor antagonists and 5ht3 receptor antagonists for the treatment of emesis
HUP0001089A2 (hu) Gyógyászati készítmények férfiak erekciós zavarainak kezelésére
BR9910180A (pt) Composição farmacêutica, processos para o tratamento de uma condição associada com a transmissão reduzida de nicotina, para identificação de um modulador positivo de um agonista receptor nicotìnico e para identificação de um composto, composto, e, uso de um modulador positivo de um agonista receptor nicotìnico
DE69734006D1 (de) Verfahren zur erleichterung von schmerzen durch eine kombination von tramadol und einen nmda-antagonist
EP1199069A3 (en) Use of an estrogen agonist/antagonist for assessing, improving, or maintaining urogenital health
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
BR0311375A (pt) Composição farmacêutica, uso da mesma, e, método para o tratamento de demência ou dano cognitivo suave em um mamìfero
BR0311898A (pt) Tratamento de associação para depressão e ansiedade com antagonistas de nk1 e nk3
BR9814923A (pt) Método para tratamento de doença de alzheimer
TW200631956A (en) Azabenzoxazoles for the treatment of CNS disorders
ZA958173B (en) Use of a serotonin agoinist in combination with a tachykinin receptor antaonist in the treatment or prevention of migraine
BR0200246A (pt) Tratamento de combinação para a depressão
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
BR0311903A (pt) Tratamento para depressão e ansiedade pela combinação de um inibidor de pde iv e um agente antidepressivo ou ansiolìtico
EP1192952A3 (en) Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
BR0005319A (pt) Tratamento combinado para depressão e ansiedade

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 10 (VIII), 13 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.